Home » Stocks » Akari Therapeutics

Akari Therapeutics, PLC (AKTX)

Stock Price: $1.90 USD 0.04 (2.15%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 63.57M
Revenue (ttm) n/a
Net Income (ttm) -17.11M
Shares Out 33.46M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $1.90
Previous Close $1.86
Change ($) 0.04
Change (%) 2.15%
Day's Open 1.87
Day's Range 1.82 - 1.91
Day's Volume 286,311
52-Week Range 0.87 - 3.35

More Stats

Market Cap 63.57M
Enterprise Value 57.84M
Earnings Date (est) Sep 24, 2020
Ex-Dividend Date n/a
Shares Outstanding 33.46M
Float 13.75M
EPS (basic) -0.1
EPS (diluted) -0.93
FCF / Share -0.07
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 82,547
Short Ratio 0.38
Short % of Float n/a
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 35.01
Revenue n/a
Operating Income -16.94M
Net Income -17.11M
Free Cash Flow -12.92M
Net Cash 5.73M
Net Cash / Share 0.17
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -145.79%
ROE -1,182.27%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.90
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-16.94-19.97-37.77-27.25-30.58-1.92-3.61-3.67-2.25-0.79
Net Income-17.11-16.47-35.40-18.14-45.32-1.95-3.62-4.27-2.12-0.68
Shares Outstanding1,8311,5401,2471,17885285.5221.0812.4611.9211.42
Earnings Per Share-0.10-0.10-0.30-0.20-0.50-0.20-1.70-3.50-1.80-0.60
Operating Cash Flow-12.92-22.58-31.60-24.62-4.97-1.48-5.45-2.13-1.01-0.37
Capital Expenditures---0.04-0.05-0.01-----
Free Cash Flow-12.92-22.58-31.64-24.68-4.98-1.48-5.45-2.13-1.01-0.37
Cash & Equivalents5.735.9728.2544.2669.063.337.661.100.010.00
Total Debt-----0.53-0.90--
Net Cash / Debt5.735.9728.2544.2669.062.797.660.210.010.00
Book Value-1.773.1117.1534.1048.722.225.81-3.36-2.49-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akari Therapeutics, PLC
Country United Kingdom
Employees 10
CEO Clive Stuart Richardson

Stock Information

Ticker Symbol AKTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKTX


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.